Double-blind treatment of major depression with dehydroepiandrosterone

American Journal of Psychiatry

Volumn 156, Issue 4, 1999, Pages 646-649

  Wolkowitz, Owen M ^a   Reus, Victor I ^a   Keebler, Audrey ^a   Nelson, Nicola ^a   Friedland, Mirit ^a   Brizendine, Louann ^a   Roberts, Eugene ^a  

^a Box F 0984 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO; PRASTERONE;

ACNE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; HIRSUTISM; HORMONE ACTION; HUMAN; MENTAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; DEHYDROEPIANDROSTERONE; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 0032938476     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Morley JE, Kaiser F, Raum WJ, Perry HM, Rood JF, Jensen J, Silver AJ, Roberts E: Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci USA 1997; 94: 7537-7542
2. Regelson W, Kalimi M: Dehydroepiandrosterone (DHEA)-the multifunctional steroid, II: effects on the CNS, cell proliferation, metabolic and vascular, clinical and other effects: mechanism of action? Ann NY Acad Sci 1994; 719:564-575
3. Sands DE, Chamberlain GHA: Treatment of inadequate personality in juveniles by dehydroisoandrosterone: preliminary report. BMJ 1952; 2:66-68
4. Strauss EB, Sands DE, Robinson AM, Tindall WJ, Stevenson WAH: Use of dehydroisoandrosterone in psychiatric treatment: a preliminary survey. BMJ 1952; 2:64-66
5. Strauss EB, Stevenson WAH: Use of dehydroisoandrosterone in psychiatric practice. J Neurol Neurosurg Psychiatry 1955; 18:137-144
6. Sands D: Further studies on endocrine treatment in adolescence and early adult life. J Ment Sci 1954; 100:211-219
7. Morales AJ, Nolan JJ, Nelson JC, Yen SS: Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78:1360-1367; correction, 1995; 80:2799
8. Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, Ormiston S, Johnson R, Canick J, Brizendine L, Weingartner H: Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997; 41:311-318
9. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
10. Calabrese VP, Isaacs ER, Regelson W: Dehydroepiandosterone in multiple sclerosis: positive effects on the fatigue syndrome in a non-randomized study, in The Biologic Role of Dehydroepiandrosterone (DHEA). Edited by Kalimi M, Regelson W. Berlin, W de Gruyter, 1990, pp 95-100
11. Roberts E, Fauble T: Oral dehydroepiandrosterone in multiple sclerosis: results of a phase one, open study. Ibid, pp 81-94
12. van Vollenhoven RF, Engleman EG, McGuire JL: An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1994; 37:1305-1310
13. Scali G, Nonis E, Petronio G, Casa B: Impiego del dinistile e dell'astenile nelle forme neurastheiche e depressive in geriatria. G Ital Richerche Clin Ter 1980; 85:85-87
14. Pelliccioni E, Nonis E, Ronchini P, Rizzi C, Scali M: Impiego del deidroandrosterone nelle forme neuroasteniche e depressive in geriatria. G Gerontol 1981; 29:602-603
15. Wolf OT, Neumann O, Hellhammer DH, Geiben AC, Strasburger CJ, Dressendorfer RA, Pirke KM, Kirschbaum C: Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 1997; 82:2363-2367
16. Forrest AD, Drewery J, Fotherby K, Laverty SG: A clinical trial of dehydroepiandrosterone (Diandrone). J Neurol Neurosurg Psychiatry 1960; 23:52-55
17. Yaffe K, Ettinger B, Pressman A, Seeley D, Whooley M, Schaefer C, Cummings S: Neuropsychiatric function and dehydroepiandrosterone sulfate in elderly women: a prospective study. Biol Psychiatry 1998; 43:694-700
18. Berr C, Lafont S, Debuire B, Dartigues JF, Baulieu EE: Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proc Natl Acad Sci USA 1996; 93:13410-13415
19. Legrain S, Berr C, Frenoy N, Gourlet V, Debuire B, Baulieu EE: Dehydroepiandrosterone sulfate in a long-term care aged population. Gerontology 1995; 41:343-351
20. Labbate LA, Fava M, Oleshansky M, Zoltec J, Littman A, Harig P: Physical fitness and perceived stress: relationships with coronary artery disease risk factors. Psychosomatics 1995; 36:555-560
21. Diamond P, Brisson GR, Candas B, Peronnet F: Trait anxiety, submaximal physical exercise and blood androgens. Eur J Appl Physiol 1989; 58:699-704
22. Fava M, Littman A, Lamon-Fava S, Milani R, Shera D, MacLaughlin R, Cassem E, Leaf A, Marchi B, Bolognesi E: Psychological, behavioral and biochemical risk factors for coronary artery disease among American and Italian male corporate managers. Am J Cardiol 1992; 70:1412-1416
23. Gray A, Jackson DN, McKinlay JB: The relation between dominance, anger, and hormones in normally aging men: results from the Massachusetts Male Aging Study. Psychosom Med 1991; 53:375-385
24. Hermida RC, Halberg F, del Pozo F: Chronobiologic pattern discrimination of plasma hormones, notably DHEA-S and TSH, classifies an expansive personality. Chronobiologia 1985; 12:105-136
25. Klinteberg B, Hallman J, Oreland L, Wirsen B, Levander SE, Schalling D: Exploring the connections between platelet monoamine oxidase activity and behavior, II: impulsive personality without neuropsychological signs of disinhibition in Air Force pilot recruits. Neuropsychobiology 1992; 26:136-145
26. Tollefson GD, Haus E, Garvey MJ, Evans M, Tuason VB: 24 hour urinary dehydroepiandrosterone sulfate in unipolar depression treated with cognitive and/or pharmacotherapy. Ann CNn Psychiatry 1990; 2:39-45
27. Hansen CR Jr, Kroll J, Mackenzie TB: Dehydroepiandrosterone and affective disorders (letter). Am J Psychiatry 1982; 139:386-387
28. Ferguson HC, Bartram ACG, Fowlie HC, Cathro DM, Birchall K, Mitchell FL: A preliminary investigation of steroid excretion in depressed patients before and after electroconvulsive therapy. Acta Endocrinol (Copenh) 1964; 47:58-66
29. Goodyer IM, Herbert J, Altham PM, Pearson J, Secher SM, Shiers HM: Adrenal secretion during major depression in 8-to 16-year-olds, I: altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone (DHEA) at presentation. Psychol Med 1996; 26:245-256
30. Reus VI, Wolkowitz OM, Roberts E, Chan T, Turetsky N, Manfredi F, Weingartner H: Dehydroepiandrosterone (DHEA) and memory in depressed patients (abstract). Neuropsychopharmacology 1993; 9:66S
31. Fava M, Rosenbaum JF, MacLaughlin RA, Tesar GE, Pollack MH, Cohen LS, Hirsch M: Dehydroepiandrosterone-sulfate/ cortisol ratio in panic disorder. Psychiatry Res 1989; 28:345-350
32. Goodyer IM, Herbert J, Altham PM: Adrenal steroid secretion and major depression in 8-to 16-year-olds, III: influence of cortisol/DHEA ratio at presentation on subsequent rates of disappointing life events and persistent major depression. Psychol Med 1998; 28:265-273
33. Osran H, Reist C, Chen C-C, Lifrak ET, Chicz-DeMet A, Parker LN: Adrenal androgens and cortisol in major depression. Am J Psychiatry 1993; 150:806-809
34. Kalimi M, Shafagoj Y, Loria R, Padgett D, Regelson W: Antiglucocorticoid effects of dehydroepiandrosterone (DHEA). Mol Cell Biochem 1994; 131:99-104
35. Browne ES, Wright BE, Porter JR, Svec F: Dehydroepiandrosterone: antiglucocorticoid action in mice. Am J Med Sci 1992; 303:366-371
36. Majewska MD: Neurosteroids: endogenous bimodal modulators of the GABAA receptor: mechanism of action and physiological significance. Prog Neurobiol 1992; 38:379-395
37. Bergeron R, de Montigny C, Debonnel G: Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated by sigma receptors. J Neurosci 1996; 16:1193-1202
38. 3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus. Proc Natl Acad Sci USA 1995; 92:3774-3778
39. Abadie JM, Wright B, Correa G, Browne ES, Porter JR, Svec F, Obesity Research Program: Effect of dehydroepiandrosterone on neurotransmitter levels and appetite regulation of the obese Zucker rat. Diabetes 1993; 42:662-669
40. van Vollenhoven RF: Dehydroepiandrosterone: uses and abuses, in Textbook of Rheumatology, Update Series 25. Edited by Kelley WN, Harris ED Jr, Ruddy S, Sledge CB. Philadelphia, WB Saunders, 1997, pp 1-25
41. Howard JS III: Severe psychosis and the adrenal androgens. Integr Physiol Behav Sci 1992; 27:209-215
42. Hayashi F, Tamura H, Yamada J, Kasai H, Suga T: Characteristics of the hepatocarcinogenesis caused by dehydroepiandrosterone, a peroxisome proliferator, in male F-344 rats. Carcinogenesis 1994; 15:2215-2219
43. Schwartz AG, Whitcomb JM, Nyce JW, Lewbart ML, Pashko LL: Dehydroepiandrosterone and structural analogs: a new class of cancer chemo-preventive agents. Adv Cancer Res 1988; 51:391-424
44. Dybing E, Sanner T: [Peroxisome proliferation and possible cancer hazard]. Tidsskr Nor Laegeforen 1995; 115:1839-1841 (Norwegian)
45. Jones JA, Nguyen A, Straub M, Leidich RB, Veech RL, Wolf S: Use of DHEA in a patient with advanced prostate cancer: a case report and review. Urology 1997; 50:784-788
46. Murphy BE: Steroids and depression. J Steroid Biochem Mol Biol 1991; 38:537-559
47. Murphy BEP, Wolkowitz OM: The pathophysiologic significance of hyperadrenocorticism: antiglucocorticoid strategies. Psychiatr Annals 1993; 23:682-690
48. Wolkowitz OM, Reus VI, Manfredi F, Ingbar J, Brizendine L, Weingartner H: Ketoconazole administration in hypercortisolemic depression. Am J Psychiatry 1993; 150:810-812
49. Reus VI, Wolkowitz OM, Frederick S: Antiglucocorticoid treatments in psychiatry. Psychoneuroendocrinology 1997; 22(suppl 1):S121-S124